Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047377282> ?p ?o ?g. }
- W2047377282 endingPage "1088" @default.
- W2047377282 startingPage "1081" @default.
- W2047377282 abstract "Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors present here nintedanib (BIBF 1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also FGFR and PDGFR. All the available clinical information regarding Phase I – II trials and the toxicity and efficacy of BIBF 1120 both as single agent and in combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is reviewed and discussed here. Expert opinion: Up till now, Phase I and II trials with nintedanib showed an improvement for survival of advanced NSCLC patients. Tolerability profile seems to be acceptable in these clinical trials. However, Phase III trials are mandatory to translate these findings into clinical practice. The research for predictive biomarkers could improve the success of these anti-angiogenic agents." @default.
- W2047377282 created "2016-06-24" @default.
- W2047377282 creator A5004175335 @default.
- W2047377282 creator A5012572593 @default.
- W2047377282 creator A5017866134 @default.
- W2047377282 creator A5058967910 @default.
- W2047377282 creator A5060388485 @default.
- W2047377282 creator A5079185525 @default.
- W2047377282 creator A5085722313 @default.
- W2047377282 creator A5089315207 @default.
- W2047377282 date "2013-06-22" @default.
- W2047377282 modified "2023-09-23" @default.
- W2047377282 title "BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer" @default.
- W2047377282 cites W1539571840 @default.
- W2047377282 cites W1573363574 @default.
- W2047377282 cites W1603230122 @default.
- W2047377282 cites W1965727465 @default.
- W2047377282 cites W1971837077 @default.
- W2047377282 cites W1972739162 @default.
- W2047377282 cites W1977999028 @default.
- W2047377282 cites W1989664813 @default.
- W2047377282 cites W2004769542 @default.
- W2047377282 cites W2014075906 @default.
- W2047377282 cites W2014370165 @default.
- W2047377282 cites W2027239974 @default.
- W2047377282 cites W2031749466 @default.
- W2047377282 cites W2039427109 @default.
- W2047377282 cites W2064795528 @default.
- W2047377282 cites W2076415360 @default.
- W2047377282 cites W2077129920 @default.
- W2047377282 cites W2089756110 @default.
- W2047377282 cites W2091844981 @default.
- W2047377282 cites W2102996502 @default.
- W2047377282 cites W2105464202 @default.
- W2047377282 cites W2111025748 @default.
- W2047377282 cites W2112768035 @default.
- W2047377282 cites W2114940128 @default.
- W2047377282 cites W2115078104 @default.
- W2047377282 cites W2125212831 @default.
- W2047377282 cites W2126327738 @default.
- W2047377282 cites W2132365366 @default.
- W2047377282 cites W2140765540 @default.
- W2047377282 cites W2140856191 @default.
- W2047377282 cites W2157262448 @default.
- W2047377282 cites W2158366593 @default.
- W2047377282 cites W2158743409 @default.
- W2047377282 cites W2159370421 @default.
- W2047377282 cites W2166573361 @default.
- W2047377282 cites W2185838453 @default.
- W2047377282 cites W2266603910 @default.
- W2047377282 cites W2433114596 @default.
- W2047377282 cites W32080905 @default.
- W2047377282 cites W4236167056 @default.
- W2047377282 cites W4251787912 @default.
- W2047377282 cites W4253705647 @default.
- W2047377282 doi "https://doi.org/10.1517/13543784.2013.812630" @default.
- W2047377282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23790097" @default.
- W2047377282 hasPublicationYear "2013" @default.
- W2047377282 type Work @default.
- W2047377282 sameAs 2047377282 @default.
- W2047377282 citedByCount "28" @default.
- W2047377282 countsByYear W20473772822013 @default.
- W2047377282 countsByYear W20473772822014 @default.
- W2047377282 countsByYear W20473772822015 @default.
- W2047377282 countsByYear W20473772822016 @default.
- W2047377282 countsByYear W20473772822017 @default.
- W2047377282 countsByYear W20473772822018 @default.
- W2047377282 countsByYear W20473772822019 @default.
- W2047377282 countsByYear W20473772822020 @default.
- W2047377282 countsByYear W20473772822021 @default.
- W2047377282 countsByYear W20473772822022 @default.
- W2047377282 countsByYear W20473772822023 @default.
- W2047377282 crossrefType "journal-article" @default.
- W2047377282 hasAuthorship W2047377282A5004175335 @default.
- W2047377282 hasAuthorship W2047377282A5012572593 @default.
- W2047377282 hasAuthorship W2047377282A5017866134 @default.
- W2047377282 hasAuthorship W2047377282A5058967910 @default.
- W2047377282 hasAuthorship W2047377282A5060388485 @default.
- W2047377282 hasAuthorship W2047377282A5079185525 @default.
- W2047377282 hasAuthorship W2047377282A5085722313 @default.
- W2047377282 hasAuthorship W2047377282A5089315207 @default.
- W2047377282 hasBestOaLocation W20473772822 @default.
- W2047377282 hasConcept C121608353 @default.
- W2047377282 hasConcept C126322002 @default.
- W2047377282 hasConcept C143998085 @default.
- W2047377282 hasConcept C197934379 @default.
- W2047377282 hasConcept C2776056115 @default.
- W2047377282 hasConcept C2776256026 @default.
- W2047377282 hasConcept C2776694085 @default.
- W2047377282 hasConcept C2777714996 @default.
- W2047377282 hasConcept C2777802072 @default.
- W2047377282 hasConcept C2778019345 @default.
- W2047377282 hasConcept C2778341716 @default.
- W2047377282 hasConcept C2778375690 @default.
- W2047377282 hasConcept C2778439243 @default.
- W2047377282 hasConcept C2778695046 @default.
- W2047377282 hasConcept C2778820342 @default.
- W2047377282 hasConcept C2779490328 @default.